Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
K L R M LLC maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action, which represents the company's active engagement with the patent office. This action is assigned to 1 distinct examiner, CHEN, CATHERYNE, who is the only examiner currently reviewing the company's work.
The prosecution is located within 1 distinct art unit. This indicates a focused technical scope for the pending application within the biotechnology field. CHEN, CATHERYNE is the busiest examiner for the portfolio, with 1 pending office action. This examiner's individual review will determine the immediate outcome for the company's pending matter.
Because there is only 1 pending office action, the busiest examiner's workload accounts for the entire active portfolio. This concentration allows for a very specific prosecution strategy. The applicant can focus entirely on the examination style and history of CHEN, CATHERYNE within 1 distinct art unit, as there are no other competing pending matters to manage. This focused approach may lead to a more predictable prosecution process in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, CATHERYNE | 1 | 37.4% | +18.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18800611 | NUTRACEUTICAL COMPOSITION AND METHOD FOR THE PROTECTION OF HUMAN ARTERIAL ENDOTHELIAL CELLS FROM ENDOTHELIAL CELL DYSFUNCTION | CHEN, CATHERYNE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18800611 | NUTRACEUTICAL COMPOSITION AND METHOD FOR THE PROTECTION OF HUMAN ARTERIAL ENDOTHELIAL CELLS FROM ENDOTHELIAL CELL DYSFUNCTION | CHEN, CATHERYNE | 1655 | §102§112DP | Non-Final OA | — | Pending | Aug 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial